key: cord-0298085-vrd2zkg0
authors: Tremblay, C.; Beach, T. G.; Intorcia, A. J.; Walker, J. E.; Arce, R. A.; Sue, L. I.; Nelson, C. M.; Borja, C. I.; Suszczewicz, K. E.; Cline, M. P.; Hemmingsen, S. J.; Qiji, S. H.; Desforges, M.; Serrano, G. E.
title: Deafferentation of Olfactory Bulb in Subjects Dying with COVID-19
date: 2021-12-23
journal: nan
DOI: 10.1101/2021.12.21.21268119
sha: 1667e645f0ada22da9a7d1b72d5fbf2b95490de7
doc_id: 298085
cord_uid: vrd2zkg0

There have been clinical descriptions of diverse neurological effects in COVID-19 disease, involving up to 36% of patients. It appears likely that most of these are not caused by viral brain invasion but by systemic accompaniments of critical illness such as coagulopathy, deleteriously upregulated immune response, autoimmune mechanisms, hypoxia or multiorgan failure. Anosmia or hyposmia is present in a majority of COVID-19 patients, and there is early and severe involvement of the nasopharyngeal mucosa and olfactory epithelium. Preliminary studies by our group have found massive gene expression changes in olfactory bulb, but the magnitude of these changes are not different between subjects with detectable versus non-detectable olfactory bulb SARS-CoV-2 RNA. As spontaneous discharge of olfactory epithelial afferents dictates intra-olfactory bulb neurophysiological activity and connectivity, we hypothesized that olfactory bulb deafferentation during COVID-19 is responsible for a large fraction of our observed olfactory bulb transcriptional changes. As the olfactory marker protein (OMP-1) is a specific marker of olfactory epithelial afferents to the olfactory bulb and is severely depleted in animal model lesions of olfactory epithelium, we quantified OMP-1-immunoreactivity in the olfactory bulb of subjects dying with or without COVID-19. Additionally, we quantified olfactory bulb tyrosine hydroxylase (TH), which is often also reduced after olfactory epithelium lesions, and SNAP-25, a pan-synaptic marker. COVID-19 cases (n = 18) were generally elderly and were not significantly different in age or gender distribution from the non-COVID-19 cases (n = 28). Both COVID-19 and non-COVID-19 cases had a wide range of neuropathological diagnoses. The area occupied by OMP-1 immunoreactivity in COVID-19 cases was significantly less, about 60% of that in control cases but amongst subjects with COVID-19, there was no significant difference between OBT-SARS-CoV-2-PCR-positive and negative cases. There were no significant group differences for TH or SNAP-25, supporting a selective effect for OMP-1. We suggest that olfactory dysfunction, and some of the COVID-19-associated transcriptional changes that we have reported for the olfactory bulb and amygdala, may be due to olfactory bulb deafferentation and subsequent transsynaptic effects. Additionally, animal models of olfactory bulb deafferentation or bulbectomy indicate a possibility for widespread changes in interconnected brain regions, providing a possible substrate for diverse post-acute COVID-19 neurological sequelae.

The coronavirus SARS-CoV-2 is the cause of pandemic severe respiratory disease, termed COVID-19, but there have additionally been clinical descriptions of diverse neurological effects, involving up to 36% of patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . What remains unclear is whether these are caused by viral brain invasion or by systemic accompaniments of critical illness such as coagulopathy, deleteriously upregulated immune response, autoimmune mechanisms, hypoxia or multiorgan failure 11 .

More than 20 published studies have utilized RT-PCR methods to determine the presence of SARS-CoV-2 genomic fragments in postmortem brain, and although results have been variable, the most likely conclusion is that SARS-CoV-2 brain invasion occurs in only a smaller fraction of subjects, viral copy numbers are low, and proof of in situ viral CNS replication or protein synthesis is lacking 13, [31] [32] [33] [34] [35] .

Anosmia or hyposmia is present in many COVID-19 patients [36] [37] [38] and clinical, autopsy and animal model evidence has pointed to early and severe involvement of the nasopharyngeal mucosa and olfactory epithelium 27, 31, 36, [39] [40] [41] [42] [43] [44] [45] . The olfactory epithelium includes olfactory sensory neurons that project directly through the perforated cribriform plate to the intracranial olfactory bulb, making this pathway a major candidate for brain entry. Of studies localizing SARS-CoV-2 RNA in multiple brain regions of deceased COVID-19 subjects, olfactory bulb has been found to be the single most-involved area 31, 46 . Preliminary studies by our group have found massive gene expression changes in olfactory bulb 47 , with lesser but still marked changes in the amygdala, one of its main projection targets. The magnitude of these changes, however, are not different between subjects with detectable versus non-detectable olfactory bulb SARS-CoV-2 RNA. As spontaneous discharge of olfactory epithelial afferents dictates intra-olfactory bulb neurophysiological activity and connectivity 48-50 , we hypothesized that deafferentation during COVID-19 is responsible for the majority of our observed olfactory bulb transcriptional changes. As the olfactory marker protein (OMP-1) is a specific marker of olfactory epithelial afferents to the olfactory bulb 51-53 and is severely depleted in animal model lesions of olfactory epithelium 48,54-57 , we quantified OMP-1-immunoreactivity in the olfactory bulb of subjects dying with or without COVID-19. Additionally, we quantified olfactory bulb tyrosine hydroxylase (TH) 54,55,58 , which is often also reduced after olfactory epithelium lesions, and SNAP-25, a pan-synaptic marker.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

The COVID-19 subjects were derived from Banner Sun Health Research Institute (BSHRI) in Sun City, Arizona (n =18). Ethical approval for autopsy and subsequent research was obtained for all subjects through Institutional Review Board-approved protocols and informed consent documents (Western IRB, Puyallup, WA; protocols 1132516 and 20201852). Clinical and neuropathological results for some of the COVID-19 cases are described in our prior publications 46,47 and the complete set of cases used in the present study is summarized in Published diagnostic clinicopathological consensus criteria for age-related and neurodegenerative brain disease [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] were used when applicable, incorporating research clinical assessment results as well as pertinent private medical history. The histological sampling and staining incorporated the protocols recommended by the National Institute on Aging and Alzheimer's Association (NIA-AA) 69 The area occupied by stained tissue elements within the olfactory bulb nerve fiber layer and adjacent glomerular layer was determined with digital image analysis (Image J software with image processing and analysis in Java: https://imagej.nih.gov/ij/). The means of the areas occupied by staining in the 4 images were used for statistical analyses, performed using SPSS software (IBM SPSS Statistics 23.0). Methods included unpaired, two-way t-tests for continuous variables, as well as analysis of variance with post-hoc Bonferronicorrected pairwise significance testing. Fisher Exact tests were used to test for proportional differences and linear regression for relationships between continuous variables. The probability level was set at p < 0.05. Table 1 shows basic data for the cases studied. COVID-19 cases did not significantly differ in age from the non-COVID-19 cases (82.3, SD 8.9 vs 86.2, SD 9.2, respectively). Males made up 11/18 and 18/28 of the COVID-19 and non-COVID-19 cases, respectively (ns). Both COVID-19 and non-COVID-19 cases had a wide range of neuropathological diagnoses, consistent with their age and derivation from BSHRI, a research center devoted to the study of aging and neurodegenerative disease. Analysis of variance showed no significant group differences for TH ( Figure 2b ) while for SNAP-25 ( Figure   2c ) the group difference was significant; F (2,38) = 3.878; p = 0.029. Significantly less SNAP-25 staining was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101/2021.12.21.21268119 doi: medRxiv preprint present in controls with pneumonia as compared to controls without pneumonia (p = 0.025) but there were no significant differences between COVID-19 cases and all controls, or between COVID-19 cases and controls subdivided by presence or absence of pneumonia.

As COVID-19 cases differed with respect to the presence or absence of olfactory bulb SARS-CoV-2 RNA, as detected by RT-PCR, we compared immunoreactivity for the 3 antibodies in the PCR-positive and PCRnegative cases versus all controls. For OMP-1, analysis of variance showed a significant difference between groups; F (2,42) = 4.251; p = 0.02. Post hoc significance testing showed a significant difference between OBT-PCR-negative COVID-19 cases and controls (p = 0.027) but no significant difference between COVID-19 OBT-PCR-positive and PCR-negative cases. Analysis of variance of the same groups for TH or SNAP-25 staining showed no significant group differences (p = 0.239 and 0.714, respectively).

Comparing COVID-19 cases and controls for the presence or absence of a major, neuropathologicallydiagnosed neurodegenerative or cerebrovascular disease, analysis of variance showed no significant difference between groups, with any of the 3 antibodies.

COVID-19 is primarily a respiratory disease but with up to 36% of patients showing neurological effects 1-10 , there is enormous potential for this additional morbidity and so it is of high importance that the mechanisms of CNS impairment be understood. At present the relative contributions of direct viral brain invasion versus indirect factors are unclear. The most unequivocal direct viral manifestation is acute encephalitis, with a reported mortality rate of 13%, but this has been estimated to occur in only 0.2% of all cases 72 ; furthermore, this is likely an overestimate as virtually all diagnoses have been made radiologically and could not have distinguished between autoimmune mechanisms versus direct viral brain infection. Systemic accompaniments of critical illness, including coagulopathy, aberrant immune responses, hypoxia and multi-organ failure are therefore more likely to account for most of the reported COVID-19-associated neurological syndromes 11 . Postmortem brain tissue studies support this likelihood, with more than 20 published studies 11-31 using RT-PCR in general agreement that SARS-CoV-2 brain invasion occurs in only a smaller fraction of subjects, and in these the viral copy numbers are often low 13, [31] [32] [33] [34] [35] . In our own comprehensive brain mapping of SARS-CoV-2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101/2021.12.21.21268119 doi: medRxiv preprint RNA in 320 brain regions of 20 deceased COVID-19 subjects, the olfactory bulb has been found to be the single most-involved area 46,47 but still was positive in only 8 of 20 cases. More than 5,000 gene expression changes were present in the olfactory bulb in COVID-19 cases as compared to control autopsies, but there were no differences between COVID-19 cases with positive versus negative RT-PCR results 47 . Fewer gene expression changes, but still more than 1,000, were found in the amygdala, a main projection target of the olfactory bulb, despite only 2/20 cases being RT-PCR positive there. Pathway analysis for the amygdala indicated enrichment and downregulation, respectively, of immune signaling and neuronal/synaptic networks while in olfactory bulb the top upregulated pathway was related to olfactory signaling.

As SARS-CoV-2 invariably infects the nasopharyngeal mucosa and associated olfactory epithelium 27, 31, 36, [39] [40] [41] [42] [43] [44] [45] , frequently resulting in hyposmia [36] [37] [38] , we hypothesized that a large fraction of COVID-19-related olfactory bulb transcriptional changes may be due to its deafferentation during COVID-19, as spontaneous discharge of olfactory epithelial afferents is a dominant regulator of olfactory bulb neurophysiological activity and connectivity 48-50 .

In this study we report that the olfactory marker protein (OMP-1), a specific marker of olfactory epithelial afferents to the olfactory bulb 51-53 , is significantly depleted in the olfactory bulb of subjects dying with COVID- 19 . This parallels what has been reported in animal model lesions of olfactory epithelium 48,54-57 . Unlike in some animal models 54,55,58 , we did not find that olfactory bulb tyrosine hydroxylase is significantly depleted in the COVID-19 subjects, but this may be dependent on the time elapsed from deafferentation. There was no depletion of SNAP-25, a protein found in most or all neuronal synapses, supporting a selective effect of COVID-19 on olfactory epithelial axons. Neither gene expression changes or OMP-1 immunoreactivity were significantly different in COVID-19 olfactory bulbs with or without positive RT-PCR for SARS-CoV2 RNA, reinforcing an emerging recognition that CNS alterations in COVID-19 may, in the majority of subjects, occur independently of direct viral action.

We suggest that at least some of the COVID-19-associated transcriptional changes that we have reported for the amygdala may be due to transsynaptic effects initiated by olfactory bulb deafferentation, as the amygdala and other brain regions are directly innervated by the olfactory bulb. Olfactory stimulation activates neurons of the amygdala 73 , while olfactory bulbectomy in mice has been reported to cause piriform cortex . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101/2021.12.21.21268119 doi: medRxiv preprint reactions including activation of interneurons, apoptosis of pyramidal neurons and downregulation of regulatory pathways [74] [75] [76] [77] [78] [79] . A UK Biobank imaging study of 401 subjects before and after SARS-CoV-2 infection 80 found markers of tissue damage were primarily in olfactory-related brain regions including the medial and lateral orbitofrontal cortex, the anterior insula, the anterior cingulate cortex and the amygdala. Metabolic imaging in patients with "long COVID" found hypometabolism in the amygdala, hippocampus, and bilateral rectal and orbital gyri 81 , similarly to the decreased global cerebral glucose utilization reported after olfactory bulbectomy in an animal model 82 . A recent study has reported evidence that SARS-CoV-2 infection of supporting olfactory epithelium sustentacular cells may be the cause of olfactory sensory dysfunction in COVID-19 83 .

Transsynaptic changes following olfactory deafferentation may have diverse behavioral effects. Olfactory bulbectomy is the basis of a rat model of depression [84] [85] [86] associated with inflammatory and intermediate early gene expression in the amygdala 87, 88 , and olfactory bulbectomy has also been associated with memory and cognitive deficits thought to be related to basal forebrain cholinergic effects [89] [90] [91] [92] [93] [94] , providing a possible substrate for diverse post-acute COVID-19 neurological sequelae.

In conclusion, we report a significant depletion, in olfactory bulb of subjects dying with COVID-19, of OMP-1, a specific marker of primary olfactory sensory input. This may be a structural correlate of the clinical hyposmia reported for many subjects with COVID-19. Associated transsynaptic effects may result in more widespread changes in interconnected brain regions. Limitations of our study include relatively small subject numbers, especially for subgroups, and inclusion of only COVID-19 subjects with severe illness. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101/2021.12.21.21268119 doi: medRxiv preprint Table 1 . Case data. Olf. Bulb SCV2 = PCR-+ for SARS-CoV-2 in olfactory bulb; AcInf = Acute or subacute infarction or ischemic-hypoxic histological changes; AD = Alzheimer's disease; ADinsuff = AD changes insufficient for diagnosis; DLB = dementia with Lewy bodies; FTLD-TDP = frontotemporal lobar degeneration with TDP-43 proteinopathy; HS = hippocampal sclerosis; LATE = Limbic age-related TDP-43 proteinopathy; LBinsuff = Lewy body disease insufficient for diagnosis of PD or DLB; PD = Parkinson's disease; PART = primary age-related tauopathy; PSP = microscopic changes consistent with progressive supranuclear palsy; VaD = vascular dementia. For all subjects, exact age is not specified due to privacy regulations. N/A = not available or not done. Yellow = Major neuropathological diagnosis.

Case . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101/2021.12.21.21268119 doi: medRxiv preprint

Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network

Neurological involvement of coronavirus disease 2019: a systematic review

Neurologic Findings Among Inpatients with COVID-19 at a Safety-Net U.S. Hospital

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

Neurologic Involvement in COVID-19: Cause or Coincidence? A Neuroimaging Perspective

Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings

Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology

COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Series

Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription-Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue

Post-mortem persistence of SARS-CoV-2: a preliminary study

Disseminated Multifocal Intracerebral Bleeding Events in Three Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation As Rescue Therapy

Fatal central nervous system co-infection with SARS-CoV-2 and tuberculosis in a healthy child

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Invited Review: The spectrum of neuropathology in COVID-19

Neuropathological findings in two patients with fatal COVID-19

Neuropathologic features of four autopsied COVID-19 patients

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Multiorgan and Renal Tropism of SARS-CoV-2

Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients

Neuropathological Features of Covid-19

Olfactory bulb SARS-CoV-2 infection is not paralleled by the presence of virus in other central nervous system areas

Evaluation of Four Commercial Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved by Emergency-Use-Authorization in Korea

Analytical Sensitivity and Specificity of Two RT-qPCR Protocols for SARS-CoV-2 Detection Performed in an Automated Workflow

Virological assessment of hospitalized patients with COVID-2019

Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression

Smell and Taste Disturbance in COVID-19 Patients: A Prospective Multicenteric Review

Neuroplasticity in the olfactory system: differential effects of central and peripheral lesions of the primary olfactory pathway on the expression of B-50/GAP43 and the olfactory marker protein

Olfactory bulb recovery following reversible deafferentation with repeated detergent application in the adult zebrafish

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

Progressive supranuclear palsy: pathology and genetics

Neuropathology of variants of progressive supranuclear palsy

Primary age-related tauopathy (PART): a common pathology associated with human aging

Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy

Vascular dementia: diagnostic criteria for research studies

A harmonized classification system for FTLD-TDP pathology

Diagnostic criteria for Parkinson disease

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Encephalitis as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes, and predictors

Sex differences in olfactory-induced neural activation of the amygdala

Trans-neuronal modification of anterior piriform cortical circuitry in the rat

Odorant deprivation reversibly modulates transsynaptic changes in the NR2B-mediated CREB pathway in mouse piriform cortex

Cortical interneurons become activated by deafferentation and instruct the apoptosis of pyramidal neurons

Deafferentation causes apoptosis in cortical sensory neurons in the adult rat

NMDA inhibitors cause apoptosis of pyramidal neurons in mature piriform cortex: evidence for a nitric oxide-mediated effect involving inhibitory interneurons

Trans-neuronal regulation of cortical apoptosis in the adult rat olfactory system

Brain imaging before and after COVID-19 in UK

18)F-FDG brain PET hypometabolism in patients with long COVID

Olfactory bulbectomy reduces cerebral glucose utilization: 2-[14C]deoxyglucose autoradiographic study

Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb

The olfactory bulbectomized rat as a model of depression: an update

The olfactory bulbectomized rat as a model of depression

Upregulated arachidonic acid signalling in the olfactory bulbectomized rat model of depression

Prolonged c-Jun expression in the basolateral amygdala following bulbectomy: possible implications for antidepressant activity and time of onset

Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala

Activation of cholinergic system partially rescues olfactory dysfunction-induced learning and memory deficit in mice

Memantine improves cognitive deficits via KATP channel inhibition in olfactory bulbectomized mice

Memantine Improves Depressive-like Behaviors via Kir6

Channel Inhibition in Olfactory Bulbectomized Mice

Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice

Immunization Against Specific Fragments of Neurotrophin p75 Receptor Protects Forebrain Cholinergic Neurons in the Olfactory Bulbectomized Mice

Spatial memory deficits initiated by agroclavine injection or olfactory bulbectomy in rats are characterized by different levels of long-term potentiation expression in the hippocampus